Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schmittel, A.
Right arrow Articles by Keilholz, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmittel, A.
Right arrow Articles by Keilholz, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:1296, 2004
© 2004 European Society for Medical Oncology

Neomycin as secondary prophylaxis for irinotecan-induced diarrhea

The first 10% of the full text of this article appears below.

Irinotecan-based chemotherapy is widely used for colorectal cancer (CRC) and small-cell lung cancer (SCLC). Irinotecan-associated diarrhea can be dose limiting and sometimes necessitates termination of chemotherapy. Loperamide at high doses can ameliorate irinotecan-associated diarrhea, but in large trials the rate of grade III/IV diarrhea remains 16–22% [1Go, 2Go]. Irinotecan . . . [Full Text of this Article]

A. Schmittel*, K. Jahnke, E. Thiel and U. Keilholz

Charité, Campus Benjamin Franklin, Department of Medicine III (Hematology, Oncology and Transfusion Medicine), Hindenburgdamm 30, D-12200 Berlin, Germany

* E-mail: alexander.schmittel@charite.de


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?